Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here

WWW Englemed
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
Lockdown leads to double unplanned pregnancies
Fri October 22nd - Unplanned pregnancies almost doubled during the first lockdown in the UK, a major study reports today. More
Promising development in treatment for glioblastoma multiforme
Fri October 22nd - A major advance in brain tumour research could pave the way for personalised treatment for the most deadly form of the disease, British scientists say. More
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote: on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...

Mitochondria mutations that may combat cancer

Friday April 9th 2021

Mitochondrial DNA mutations found in cancer tumours are linked to improved chances of survival, researchers have found.

The discovery has created a puzzle for scientists to establish what the has caused the mutations and what their role is. But Cancer Research UK scientists said they were optimistic it would open the way to new therapies.

Researchers at the Cancer Research UK Beatson Institute in Glasgow, UK, and the Memorial Sloan Kettering Cancer Center in New York, USA, have found that patients with colorectal cancer had a 57% to 93% lower mortality risk from their cancer, depending on the type of mitochondrial DNA mutation.

They hope these findings will enable doctors to identify patients with more aggressive forms of bowel cancer so they can receive the most effective treatments.

The study, published in Nature Metabolism, collated and analysed data from the largest published dataset of tumour samples that include mitochondrial genome data and the corresponding clinical outcomes of the patients.

By analysing this data from 344 patients with colorectal cancer, the researchers matched groups of mutations to the likelihood of survival, finding the 57% to 93% decreased risk of death from colorectal cancer.

The researchers went on to examine existing data from more than 10,000 tumour samples across 23 cancer types to look for frequently repeated mitochondrial mutations and found they were present in almost six in 10 of the tumour samples, with 25 out of the 30 most commonly mutated genes across cancers being present in the mitochondrial genome.

Dr Payam Gammage, co-lead author and group leader at the Cancer Research UK Beatson Institute, said: “This new study shines a light on the impact of mitochondrial DNA mutations in cancer, which have been overlooked for decades.

“This discovery could have a huge impact on patient care, with potential for changes to suggested treatments and a patient’s outlook based upon the mitochondrial DNA status of their cancer. However, further research will be necessary to move these discoveries from the lab to the clinic.”

Dr Ed Reznik, co-lead author based at Memorial Sloan Kettering Cancer Center, added: “Using data hiding in plain sight, we have shown that a critical piece of the cell’s machinery to make energy is quite often broken in cancers. It now begs the question of how these mutations within mitochondrial DNA might be exploited as drug targets.”

The research was funded by Cancer Research UK.

Nature Metabolism 8 April 2021


Tags: Cancer | Gastroenterology | Genetics | North America | UK News

Printer friendly page Printer friendly page

Comment on this article:

<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)